Moleculin Biotech Beheer

Beheer criteriumcontroles 2/4

De CEO Moleculin Biotech is Wally Klemp, benoemd in Jul2015, heeft een ambtstermijn van 9.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.41M, bestaande uit 39.9% salaris en 60.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.43% van de aandelen van het bedrijf, ter waarde $ 191.09K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.1 jaar en 2.7 jaar.

Belangrijke informatie

Wally Klemp

Algemeen directeur

US$1.4m

Totale compensatie

Percentage CEO-salaris	39.9%
Dienstverband CEO	9.3yrs
Eigendom CEO	2.4%
Management gemiddelde ambtstermijn	7.1yrs
Gemiddelde ambtstermijn bestuur	2.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Wally Klemp's beloning veranderd ten opzichte van Moleculin Biotech's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$30m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$27m
Dec 31 2023	US$1m	US$565k	-US$30m
Sep 30 2023	n/a	n/a	-US$26m
Jun 30 2023	n/a	n/a	-US$29m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$2m	US$565k	-US$29m
Sep 30 2022	n/a	n/a	-US$25m
Jun 30 2022	n/a	n/a	-US$21m
Mar 31 2022	n/a	n/a	-US$18m
Dec 31 2021	US$2m	US$538k	-US$16m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$15m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$2m	US$500k	-US$17m
Sep 30 2020	n/a	n/a	-US$19m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	US$2m	US$625k	-US$13m
Sep 30 2019	n/a	n/a	-US$12m
Jun 30 2019	n/a	n/a	-US$10m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$1m	US$403k	-US$12m
Sep 30 2018	n/a	n/a	-US$12m
Jun 30 2018	n/a	n/a	-US$13m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$1m	US$325k	-US$10m

Compensatie versus markt: De totale vergoeding ($USD 1.41M ) Wally } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 353.74K ).

Compensatie versus inkomsten: De vergoeding van Wally is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Wally Klemp (64 yo)

9.3yrs

Tenure

US$1,414,599

Compensatie

Mr. Walter V. Klemp, also known as Wally, has been the Executive Chairman of Autonomix Medical, Inc. since joining in January 2022. He Co-Founded Moleculin Biotech, Inc. in July 2015 and has been its Chief...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Walter Klemp	Co-Founder	9.3yrs	US$1.41m	2.43% $ 191.1k
Jonathan Foster	Executive VP & CFO	8.3yrs	US$840.64k	0.38% $ 29.8k
Donald Picker	Chief Scientific Officer	7.3yrs	US$599.11k	0.27% $ 21.0k
Waldemar Priebe	Co-Founder	no data	geen gegevens	geen gegevens
John Waymack	Senior Chief Medical Officer	3.1yrs	geen gegevens	geen gegevens
Sandra Silberman	Chief Medical Officer of New Products	7yrs	geen gegevens	geen gegevens
Wolfram C. Dempke	European Chief Medical Officer	2.5yrs	geen gegevens	geen gegevens

7.1yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0K2H is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Walter Klemp	Co-Founder	9.3yrs	US$1.41m	2.43% $ 191.1k
Waldemar Priebe	Co-Founder	no data	geen gegevens	geen gegevens
Michael Cannon	Independent Director	8.4yrs	US$68.52k	0% $ 0
Jorge Cortes	Member of Scientific Advisory Board (SAB)	no data	geen gegevens	geen gegevens
Daniel Von Hoff	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Andreeff	Member of Scientific Advisory Board (SAB)	no data	geen gegevens	geen gegevens
John Climaco	Lead Independent Director	7.3yrs	US$81.05k	0% $ 0
Elizabeth Cermak	Independent Director	4.1yrs	US$63.52k	0% $ 0
Martin Tallman	Member of Annamycin Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Robert George	Independent Director	8.4yrs	US$74.90k	0.033% $ 2.6k
Joy Yan	Independent Director	2.7yrs	US$47.15k	0% $ 0
Giovanni Martinelli	Member of Scientific Advisory Board (SAB)	no data	geen gegevens	geen gegevens

2.7yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0K2H wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.7 jaar), wat duidt op een nieuw bestuur.

Moleculin Biotech Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman

Moleculin Biotech, Inc., Annual General Meeting, Jun 15, 2023

Founder recently bought US$58k worth of stock

Founder recently bought US$108k worth of stock

Moleculin Biotech, Inc. Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

Recent updates

New major risk - Shareholder dilution

Moleculin Biotech, Inc. Announces New Findings Supporting the Ability of Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Biotech, Inc. Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

New major risk - Financial position

Moleculin Biotech, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

New major risk - Shareholder dilution

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.497817 million.

Moleculin Biotech, Inc. Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Moleculin Biotech, Inc. Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

New major risk - Market cap size

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)

Moleculin Biotech, Inc. to Report Q1, 2024 Results on May 10, 2024

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman

New major risk - Market cap size

Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

Moleculin Biotech, Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

Moleculin Biotech, Inc. Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Moleculin Biotech, Inc. announced that it expects to receive $9.01739 million in funding

New major risk - Financial position

Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

Moleculin Biotech, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Moleculin Biotech Receives an Extension of the 180 Calendar Days from Nasdaq to Regain Compliance with the Bid Price Requirement

Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

New major risk - Financial position

Moleculin Biotech, Inc. Provides Update on Ongoing Clinical Trials

Moleculin Biotech, Inc. to Report Q2, 2023 Results on Aug 11, 2023

Moleculin Biotech, Inc., Annual General Meeting, Jun 15, 2023

Moleculin Biotech Receives Non-Compliance Notice From Nasdaq

Moleculin Biotech, Inc. to Report Q1, 2023 Results on May 11, 2023

Moleculin Biotech, Inc. Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Founder recently bought US$58k worth of stock

Founder recently bought US$108k worth of stock

Moleculin Biotech, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Moleculin Biotech, Inc Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces WP1096 Molecule Will Be Evaluated in Animal Studies Through the Preclinical Services Offered by the National Institute of Allergy and Infectious Diseases

Moleculin Biotech, Inc. Announces Completion of Third Single Ascending Dose Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Concludes Phase 1B and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces Completion of First Single Ascending Dose (Sad) Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

Moleculin Biotech, Inc. Receives Allowance to Proceed with Phase 1/2 Study of Annamycin

Moleculin Biotech, Inc. Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

Moleculin Biotech, Inc. Receives IND Clearance to Conduct Phase 1 Study of WP1066 for Treatment of Recurrent Malignant Glioma

Moleculin Biotech, Inc., Annual General Meeting, May 26, 2022

Moleculin Biotech, Inc. Announces Presentation of Positive Preclinical Annamycin Data At the AACR 2022 Annual Meeting

Moleculin Biotech, Inc. Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma

High number of new and inexperienced directors

Moleculin Biotech, Inc. Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme

High number of new and inexperienced directors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd